PHK
ESPR

Point72 Hong Kong’s Esperion Therapeutics ESPR Stock Holding History

Point72 Hong Kong’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,641
Closed -$105K – 593
2022
Q3 		$105K Buy
+15,641
New +$107K ﹤0.01% 1219
2021
Q4 		– Sell
-1,644
Closed -$20K – 2028
2021
Q3 		$20K Sell
1,644
-5,933
-78% -$86.4K ﹤0.01% 1704
2021
Q2 		$160K Buy
+7,577
New +$182K 0.01% 1206
2021
Q1 		– Sell
-1,475
Closed -$38K – 1913
2020
Q4 		$38K Buy
1,475
+1,054
+250% +$31.6K ﹤0.01% 1302
2020
Q3 		$16K Sell
421
-3,328
-89% -$132K ﹤0.01% 911
2020
Q2 		$192K Buy
+3,749
New +$157K 0.02% 514
2019
Q3 		– Sell
-1,030
Closed -$48K – 1101
2019
Q2 		$48K Sell
1,030
-329
-24% -$15.5K 0.01% 641
2019
Q1 		$55K Buy
+1,359
New +$61K 0.02% 516
2018
Q4 		– Sell
-21
Closed -$1K – 977
2018
Q3 		$1K Buy
+21
New +$964 ﹤0.01% 811
2018
Q2 		– Sell
-664
Closed -$48K – 971
2018
Q1 		$48K Buy
+664
New +$48.8K 0.02% 461

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Point72 Hong Kong's ESPR Position: Q4 2022 in Review

Point72 Hong Kong sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 15,641 shares — an estimated $105K sold.

Point72 Hong Kong first reported a position in ESPR in Q1 2018 and held it in 10 quarters. The position peaked at $192K in Q2 2020. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Point72 Hong Kong reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 15,641 Esperion Therapeutics shares in Q4 2022, an estimated $105K.
  • Point72 Hong Kong first reported a position in Esperion Therapeutics in Q1 2018 and held it in 10 quarters.
  • Point72 Hong Kong's Esperion Therapeutics position peaked at $192K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.